NCT06278051View on ClinicalTrials.gov

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

CompletedOBSERVATIONAL
Enrollment

320

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions
Venous Thromboembolism
Interventions
DRUG

Rivaroxaban granules for oral suspension

Treatment dose and period decided by its prescription

DRUG

Warfarin

Treatment dose and period decided by its prescription

Trial Locations (2)

Unknown

Many facilities, Multiple Locations

530-0001

Bayer, Osaka

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical Research & Development L.L.C.)

UNKNOWN

lead

Bayer

INDUSTRY

NCT06278051 - An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism | Biotech Hunter | Biotech Hunter